 |
The Journal of Neuroscience, October 18, 2006, 26(42):10911-10915; doi:10.1523/JNEUROSCI.1810-06.2006
Previous Article | Next Article 
Brief Communications
Dysregulation of Brain-Derived Neurotrophic Factor Expression and Neurosecretory Function in Mecp2 Null Mice
Hong Wang,1
Shyue-an Chan,2
Michael Ogier,1
David Hellard,1
Qifang Wang,1
Corey Smith,2 and
David M. Katz1
Departments of 1Neurosciences and 2Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-4975
Correspondence should be addressed to Dr. David M. Katz, Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106-4975. Email: david.katz{at}case.edu
Disruptions in brain-derived neurotrophic factor (BDNF) expression are proposed to contribute to the molecular pathogenesis of Rett syndrome (RTT), a severe neurological disorder caused by loss-of-function mutations in methyl-CpG-binding protein-2 (MeCP2). Although MeCP2 is a transcriptional regulator of BDNF, it is unknown how MeCP2 mutations affect transynaptic BDNF signaling. Our findings demonstrate an early, abnormal neurosecretory phenotype in MeCP2-deficient neurons characterized by significant increases in the percentage of cellular BDNF content available for release. However, loss of MeCP2 also results in deficits in total cell BDNF content that are developmentally regulated in a cell-type-specific manner. Thus, the net effect of MeCP2 loss on absolute BDNF secretion changes with age and is determined by both the amount of BDNF available for release and progressive declines in total cellular BDNF. We propose, therefore, that loss of MeCP2 function disrupts transynaptic BDNF signaling by perturbing the normal balance between BDNF protein levels and secretion. However, mutant neurons are capable of secreting wild-type levels of BDNF in response to high-frequency electrical stimulation. In addition, we found elevated exocytic function in Mecp2/y adrenal chromaffin cells, indicating that the Mecp2 null mutation is associated with alterations of neurosecretion that are not restricted to BDNF. These findings are the first examples of abnormal neuropeptide and catecholamine secretion in a mouse model of RTT.
Key words: Rett syndrome; BDNF; nodose ganglion; chromaffin cells; dense-core vesicles; readily releasable pool
Received May 8, 2006;
revised Sept. 9, 2006;
accepted Sept. 11, 2006.
Correspondence should be addressed to Dr. David M. Katz, Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106-4975. Email: david.katz{at}case.edu
Related articles in J. Neurosci.:
- This Week in The Journal
J. Neurosci. 2006 26: i.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
Y. Hayano and N. Yamamoto
Activity-Dependent Thalamocortical Axon Branching
Neuroscientist,
August 1, 2008;
14(4):
359 - 368.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Percy
Rett Syndrome: Recent Research Progress
J Child Neurol,
May 1, 2008;
23(5):
543 - 549.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kron, J. Reuter, E. Gerhardt, T. Manzke, W. Zhang, and M. Dutschmann
Emergence of brain-derived neurotrophic factor-induced postsynaptic potentiation of NMDA currents during the postnatal maturation of the Kolliker-Fuse nucleus of rat
J. Physiol.,
May 1, 2008;
586(9):
2331 - 2343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ogier, H. Wang, E. Hong, Q. Wang, M. E. Greenberg, and D. M. Katz
Brain-Derived Neurotrophic Factor Expression and Respiratory Function Improve after Ampakine Treatment in a Mouse Model of Rett Syndrome
J. Neurosci.,
October 3, 2007;
27(40):
10912 - 10917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kron, M. Morschel, J. Reuter, W. Zhang, and M. Dutschmann
Developmental changes in brain-derived neurotrophic factor-mediated modulations of synaptic activities in the pontine Kolliker Fuse nucleus of the rat
J. Physiol.,
August 15, 2007;
583(1):
315 - 327.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|